A new weight-based secukinumab formulation provides a new option for treatment of adolescents with moderate-to-severe hidradenitis suppurativa (HS) with the FDA’s approval, according to a press ...
The FDA approved secukimumab for children aged 12 years and older with moderate to severe hidradenitis suppurativa, Novartis announced in a press release.The approval makes secukinumab (Cosentyx) the ...
The FDA has approved secukinumab (Cosentyx; Novartis) for the treatment of pediatric patients 12 years and older with moderate to severe hidradenitis suppurativa (HS), the company announced. 1 The ...
Living with scars can be difficult. A scar can change the way you think about and see yourself, but it can also affect your life in bigger ways. Some scars can even limit your motion. There are ...
When you have vasomotor symptoms, or hot flashes and night sweats, you most likely want one thing: relief. Fortunately, you have many options that can help you find just that. Prescription medications ...
Katlein Franca, MD, is a dermatologist and clinical associate professor of Dermatology & Cutaneous Surgery and Psychiatry & Behavioral Sciences at the University of Miami. Different kinds of skin ...
Pulling off a pore strip to a prickly pile of white pus may sound appealing– but is it as effective as it looks? “Pore strips usually have an adhesive that binds to pores and unclogs them,” double ...
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results